Agefocus
Regenerative & Healing

BPC-157

Tissue repair and gut healing peptide

Subcutaneous Injection Oral Intramuscular Injection
Accelerated wound healing Gut healing and protection Tendon and ligament repair Neuroprotective effects Anti-inflammatory

Overview

BPC-157 (Body Protection Compound-157) is a 15-amino acid peptide derived from human gastric juice. It exhibits remarkable tissue-healing properties across virtually every tissue type studied, including gut, tendons, ligaments, muscles, nerves, and brain.

Mechanism of Action

Upregulates VEGF and GH receptors → promotes angiogenesis → accelerates nitric oxide pathway → modulates dopamine and serotonin systems → activates FAK-paxillin pathway for cell migration → cytoprotective via multiple redundant pathways.

Benefits

  • Accelerated wound healing
  • Gut healing and protection
  • Tendon and ligament repair
  • Neuroprotective effects
  • Anti-inflammatory
  • Counters NSAID damage

Dosing Protocol

Typical Dose250–500 mcg/day
Frequency1–2x daily (SubQ near injury, or systemic)
Cycle Length4–12 weeks

Half-Life

~4 hours

Duration of pharmacological activity after administration.

Side Effects

  • Minimal reported side effects
  • Injection site irritation
  • Nausea (oral, rare)
  • Extremely well-tolerated

Stacking Recommendations

TB-500 (ultimate healing stack)GHK-CuThymosin Alpha-1

Storage & Reconstitution

Lyophilized: -20°C stable for years. Reconstituted: 2–8°C, use within 21 days.

Research Notes

Over 100 published studies demonstrating tissue repair across organ systems. No reported toxicity at any dose. Being studied for IBD, traumatic brain injury, and various GI conditions. Human clinical trials underway.

Medical Disclaimer

This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment recommendations. Peptide therapy should only be initiated under the supervision of a qualified healthcare provider. Individual results may vary. Always consult with your physician before starting any new therapy. Regulatory status varies by jurisdiction.